Trial Profile
A Phase 1, Open-Label, Randomized, Three-Period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and VYVANSE, Administered Alone and in Combination in Healthy Adult Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Guanfacine (Primary) ; Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder; Bipolar disorders; Eating disorders; Generalised anxiety disorder; Social phobia
- Focus Pharmacokinetics
- Sponsors Shire
- 19 Aug 2009 Status changed from active, no longer recruiting to completed as reported by CLinicalTrials.gov
- 16 Jul 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 17 Jun 2009 New trial record